# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:VRNA) with a Buy and lowers the price tar...
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an ...
Piper Sandler analyst Yasmeen Rahimi maintains Verona Pharma (NASDAQ:VRNA) with a Overweight and raises the price target fro...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...
Wedbush analyst Liana Moussatos reiterates Verona Pharma (NASDAQ:VRNA) with a Outperform and maintains $33 price target.
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...